Testing riliprubart vs. standard IVIg for CIDP
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CIDP (typical, motor, or multifocal type) as confirmed by a study doctor.
- You must have had a good response to IVIg treatment within the last 5 years.
- You must be on a stable, regular dose of IVIg.
- You must have some residual symptoms (disability) from CIDP, like weakness or numbness.
- You must have had at least one worsening of CIDP symptoms in the last 2 years when IVIg was reduced or stopped.
- You cannot have other causes of nerve damage, like diabetes or certain infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests a new drug called Imeroprubart for people with CIDP who are already on a stable treatment like steroids or immunoglobulin. The goal is to see if the drug can help control symptoms better.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.